Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 5/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514820 | 1.00 | CNR1 (0.43) | CNR1CNR2APPPIN1MAOB | |
| SCHEMBL14616496 | 0.84 | PDE2A (0.46) | CNR1CNR2APPMAOBSMN1; SMN2 | |
| SCHEMBL9987222 | 0.84 | CNR1 (0.44) | CNR1CNR2APPPIN1MAOB | |
| SCHEMBL22323930 | 0.83 | APP (0.50) | CNR1CNR2APPPIN1MAOB | |
| SCHEMBL846643 | 0.83 | POLB (0.47) | CNR1CNR2APPPIN1MAOB | |
| SCHEMBL12423709 | 0.82 | PIN1 (0.59) | CNR1CNR2PIN1MAOBALDH1A1 | |
| SCHEMBL30683113 | 0.82 | PIN1 (0.59) | CNR1CNR2PIN1MAOBALDH1A1 | |
| SCHEMBL5258785 | 0.82 | PIN1 (0.45) | PIN1SMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL9987933 | 0.82 | PIN1 (0.44) | CNR1CNR2APPPIN1MAOB | |
| SCHEMBL9987333 | 0.82 | MAOB (0.44) | CNR1CNR2APPPIN1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018213777-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-3251674-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BioCryst Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2014078778-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-2254892-B1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2254892-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | Global Alliance For Tb Drug Development (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009120789-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | O60361, OXA1L, TBCD | CNR1 3817/4885CNR2 4296/4885APP 4428/4885 |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | CNR1 4187/4885CNR2 4733/4885APP 4874/4885 |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | CNR1 2906/4885CNR2 2908/4885APP 4504/4885 |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | CNR1 4187/4885CNR2 4733/4885APP 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.